Atrial fibrillation (AFib) is a common cardiac arrhythmia that has been reported in individuals infected with COVID-19.
A study revealed that patients who tested positive for COVID-19 had a higher likelihood of developing atrial fibrillation (AF).
This highlights the fact that COVID-19 can lead to significant diseases outside of the lungs.
The mechanisms by which COVID-19 increases the risk of AFib are not fully understood, but may involve inflammation of the heart muscle (myocarditis) or other changes in cardiac function.
Some studies have found that individuals with COVID-19 are more likely to experience AFib than those without the virus.
The risk of developing AFib may be higher in individuals with severe COVID-19 or those requiring intensive care.
The risk of AFib may be increased in individuals with underlying heart disease or other risk factors for AFib.
The risk of AFib may be higher in older individuals or those with other comorbidities.
The use of certain medications or treatments for COVID-19 may also increase the risk of AFib.
Further research is needed to fully understand the relationship between COVID-19 and AFib and to develop effective strategies for preventing and managing AFib in individuals with COVID-19.